Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
A Phase I Study of Lenalidomide Plus Pembrolizumab in Patients With Relapsed and/or Refractory Solid Tumors With Phase II Expansion in Non-small Cell Lung Cancer
Sponsor: Celgene
Terminated
Study terminated prematurely due to funding/support being withdrawn by grantor
This PHASE1/PHASE2 trial investigates Nonsmall Cell Lung Cancer and Relapsed or Refractory Solid Tumors and is currently terminated or withdrawn. Celgene leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2022 — Jun 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 7 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jul 2018 — Mar 2019 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Terminated PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
May 2017 — Apr 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- Fox Chase Cancer Center
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .